Viroblock Closes Series C Financing Round

PLAN-LES-OUATES, Switzerland, October 28, 2011 -

Viroblock S.A., a company with a highly innovative, broadly applicable anti-viral air filtration technology, initially focused on development and commercialization of anti-viral face-masks, today announced the successful closure of a 3.3 million CHF Series C financing round.

Dr Jamie Paterson, CEO of Viroblock, said “these funds allow Viroblock to complete the development of our anti-viral face-mask and start its commercialization in 2012.”  Unlike other face-masks, the Viroblock mask can kill enveloped viruses, such as H1N1, H5N1 and SARS, on pass through air.

The financing round was led by Dr Peter Pfister and Dr Erich Platzer from the StartAngels Network, with strong support from new and existing investors. Dr Platzer noted that “pathogenic respiratory viruses are an increasing concern both for professional health workers and the general public. We are therefore excited to invest in Viroblock’s unique solution to this everyday problem.”

About Viroblock

Viroblock S.A. is a Swiss-based company focused on developing a novel anti-viral technology that is both rapid acting and broad spectrum. Applied to non-woven fabric, the technology is particularly suited for air filtration products. In fact, previous work has shown Viroblock fabric to kill over 99% of H5N1 viruses when challenged in standardized aerobiology experiments.

Viroblock is currently scaling up the production of its anti-viral technology and expects to enter the market with an anti-viral mask in 2012. Visit www.viroblock.com

For further information please contact
Jamie Paterson, CEO Viroblock S.A.
+41-79-831-60-06
info@viroblock.com

Viroblock S.A.
18, chemin des Aulx
CH-1228 Plan-les-Ouates, Geneva, Switzerland
www.viroblock.com

.